GLP-1 Receptor Agonist Use and Risk of Repeat Colonoscopy: Scientific Reports Publishes a TriNetX Global Network Retrospective Cohort Study on November 11
New Taipei, Taiwan — Scientific Reports published a real-world cohort study on November 11, 2026, titled Association between GLP-1 receptor agonist use and risk of repeat colonoscopy. The authors are affiliated with Fu Jen Catholic University Hospital, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, among other institutions, with correspondence to Chun-Ying Wu.
Glucagon-like peptide-1 receptor agonists are increasingly used for diabetes and obesity, and their effects on gastrointestinal motility have raised concern about colonoscopy outcomes. The team evaluated the association between GLP-1 receptor agonist use and repeat colonoscopy and performed exploratory analyses of pre-procedural discontinuation intervals.
The study is a retrospective cohort study using the TriNetX Global Collaborative Network, restricted to adults aged 18 to 90 years. Because only de-identified data from the TriNetX research network were analysed, the institutional review board of Fu Jen Catholic University Hospital deemed the study exempt from review and waived informed consent. The study was not registered as a clinical trial.
Funding came from Fu Jen Catholic University Hospital and Taiwanese science and health authorities under the grant numbers listed in the paper, and the authors declared no competing interests. This report covers the study design and published framework only; effect-size figures should be taken from the journal text itself. The design is observational, and association does not establish causation.
Published by GSM · USA (original Chinese edition)
Photo: 图：图中是一台结肠镜模拟训练设备。图中是结肠镜模拟器的实物照片，为结肠镜题材通用配图，非本研究设备。division, CSIRO，CC BY 3.0，经Wikimedia Commons。 / Photo: file photo. division, CSIRO, CC BY 3.0, via Wikimedia Commons.
Study of Nearly 100,000 Americans Finds Thousands of New Drug-Gene Variants: At Least One Variant in 16 Pharmacogenes in Every Participant, One in Four Had Taken an Affected Medicine2026-11-11
Blood Multi-Biomarker Panel Discriminates Alzheimer Disease from Healthy Controls: 200 Participants and 12 Markers, Scientific Reports Model Reaches AUROC of 0.9999 with External Validation Still Required2026-11-11